11 COVID-19 vaccines enter clinical trials
Four of them are in Phase III clinical trials.
According to Wu Yuanbin, Director of the Department of Social Development Science and Technology of the Ministry of Science and Technology, 11 of China’s COVID-19 vaccines have entered the clinical research stage, of which three inactivated vaccines and one adenovirus vector vaccine have entered phase III clinical trials. Other recombinant protein vaccines, mRNA vaccines and attenuated influenza virus vector vaccines are in phase Ⅰ/Ⅱ clinical trials.
Four vaccines that have entered Phase III clinical trials are progressing well.
When will the COVID-19 vaccine be approved for marketing?
Yang Sheng, in charge of the Department of Drug Registration Administration of the State Drug Administration, introduced that the vaccine needs to complete preclinical studies, Phase I and Phase II clinical studies, and to pass Phase III clinical trials to prove that the safety and effectiveness of the vaccine meets the set standards before it can be marketed. In addition, a commercial scale validation should be completed to prove the acceptable safety, clear effectiveness and quality control of the proposed vaccine.
The speed of progress in a phase III clinical trial is influenced by many factors, such as the number of subjects, the number of subject groups, and the outcome.
The researchers will adopt the principle of ad hoc approach to promote the launch of our new coronavirus vaccine as soon as possible.
How long is the COVID-19 vaccine protected?
Zeng Guang, chief scientist of epidemiology at the CDC, introduced that it has only been nine months since the discovery of the new coronavirus in humans, and long-term, extensive research is needed to determine the exact length of protection of each vaccine.
At present, the serum monitoring results of the earliest vaccinated subjects in China show that the antibodies still maintain a high level, which suggests that the vaccine may have a longer-term protective effect.
How much neocon vaccine will China produce? How is it distributed?
Zheng Zhongwei, head of the vaccine development task force of the scientific research and development group, said that by next year, China’s annual production capacity of the COVID-19 vaccine can reach more than 1 billion doses. In the future, the vaccine will be arranged sequentially according to three strata of population groups: high-risk, high-risk and general population.
§ High-risk groups: staff at border crossings, city runners, cold by-product production plant staff, etc..
§ High-risk groups: the elderly, pregnant women, children, people with underlying diseases.
How is the COVID-19 vaccine priced?
Zheng Zhongwei said the pricing will be based on the public product attributes of the new coronavirus vaccine. The pricing of China’s new coronavirus vaccine will definitely be within the range acceptable to the public, and a guideline price for the new coronavirus vaccine will be put forward within the range acceptable to the public.
Do I still need to wear a mask after receiving the neocon vaccine?
Zeng Guang said that winter and spring are high times for respiratory infectious diseases, and no single neo-crown vaccine is completely effective for other respiratory infections such as influenza and adenovirus, in addition to neo-crown pneumonia. In addition, for most people, the vaccine may not be available this winter and spring.
Therefore, the decision to wear a mask is based on the prevalence of neo-coronary pneumonia and other respiratory infections in the country, ventilation measures, and autoimmune status. In particular, the elderly, patients with chronic diseases and children should be better protected.
In addition, it is recommended to maintain the good habits of wearing a mask, washing hands frequently and keeping your distance.
Source: China News Network, China CCTV News Client